Sets out Shared Intent to Support Delivery of Propanc's First-In-Human Clinical Trial for PRP
MELBOURNE, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has signed a Memorandum of Understanding (MOU) with Avance Clinical Pty Ltd. The MOU sets out the shared intent of Propanc and Avance to work together to support the clinical delivery of Propanc's Phase 1b, First-In-Human (FIH) clinical trial for PRP, Propanc's lead investigational candidate for advanced solid tumors. Importantly, both parties intend to approach the collaboration in a spirit of openness, scientific rigor, and shared problem-solving, with the goal of advancing PRP efficiently from FIH into Proof-of-Concept and, as data supports, later-phase development.
Avance Clinical is a full-service Contract Research Organization (CRO) headquartered in Australia, with extensive operations across North America, Asia Pacific, New Zealand and Europe. With more than 30 years of experience leading early phase clinical trials, they leverage the unique advantages of the Australian market, including rapid ethics approval, and up to 43.5% off with the Australian R&D tax rebate, to provide biotech companies with an accelerated pathway to clinical success. With Propanc's headquarters and wholly owned operating subsidiary, Propanc Pty Ltd, based in Melbourne, Australia, since 2007, it is ready to capitalize on these advantages in partnership with Avance Clinical.
"We are delighted to enter this Memorandum of Understanding with Avance Clinical as we prepare to initiate the First-in-Human Phase 1 clinical study of PRP, Propanc's lead oncology candidate. It represents an important milestone in our journey from preclinical development to clinical evaluation. Avance Clinical's proven expertise in the conduct of early-phase oncology studies, combined with its strong reputation for quality and regulatory excellence, makes them an ideal partner for this critical stage of development," said Mr. James Nathanielsz, Propanc's Chief Executive Officer. "The planned Phase 1b FIH study is designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary clinical activity of PRP in patients with advanced cancer. We believe that PRP's unique mechanism of action, low toxicity and good tolerability has the potential to address a significant unmet medical need and offers a novel therapeutic approach for patients with limited treatment options. We look forward to working closely with the Avance Clinical team to efficiently advance this important program and generate the clinical data necessary to support the continued development of PRP. This collaboration reflects our shared commitment to scientific excellence, patient safety, and the pursuit of innovative cancer therapies that may improve outcomes for patients worldwide."